Windlas Biotech Delivers Strong Q2 and H1 FY27 Results Driven by Core CDMO Expansion
Windlas Biotech Ltd 路 Press Release 路 05 Nov 2026, 11:18 pm
Windlas Biotech Delivers Strong Q2 and H1 FY27 Results Driven by Core CDMO Expansion Windlas Biotech reported Q2FY27 revenue of Rs. 264 crore, up 19% YoY, marked by its 15th consecutive quarter of record sales. Adjusted EBITDA rose 20% YoY to Rs. 36 crore with a 13.7% margin, while adjusted PAT increased 29% YoY to Rs. 25 crore. For H1FY27, revenue reached Rs. 512 crore (up 18% YoY), driven by Generic Formulations CDMO sales rising 32% YoY to Rs. 422 crore. The company commercialized Plant-6 in Sep'26, received EU GMP certification for Plant-4 and Plant-5, and maintained net liquidity of Rs. 223 crore.
Original exchange filing (PDF)
More announcements from Windlas Biotech Ltd
- Q2 & H1 FY27 Earnings Conference Call Transcript 路 13 Nov 2026
- Recording of Conference Call 路 07 Nov 2026
- Mr. Ashok Kumar Windlass, has been appointed, as Founder President (Senior Management Personnel) of the Company, effective from November 6, 2026. 路 05 Nov 2026
- resignation of Mr. Ashok Kumar Windlass (DIN: 00011451) from the position of Whole-time Director and Director of the Company with effect from November 5, 2026 at 10.00 A.M. 路 05 Nov 2026
- Investor Presentation - Q2 & H1FY27, 路 05 Nov 2026
- Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Approval inter alia unaudited financial results for the quarter and half year ended September 30, 2026 路 05 Nov 2026
- The Board approved inter alia financial results for the quarter and half year ended September 30 2026. 路 05 Nov 2026
